These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22429800)

  • 21. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
    Kakkar AK; Brenner B; Dahl OE; Eriksson BI; Mouret P; Muntz J; Soglian AG; Pap AF; Misselwitz F; Haas S;
    Lancet; 2008 Jul; 372(9632):31-9. PubMed ID: 18582928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data.
    Kwong LM
    Vasc Health Risk Manag; 2011; 7():461-6. PubMed ID: 21822393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
    Cao YB; Zhang JD; Shen H; Jiang YY
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1099-108. PubMed ID: 20812009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
    Lu X; Lin J
    BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
    Lassen MR; Davidson BL; Gallus A; Pineo G; Ansell J; Deitchman D
    J Thromb Haemost; 2007 Dec; 5(12):2368-75. PubMed ID: 17868430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban or Enoxaparin.
    Ricket AL; Stewart DW; Wood RC; Cornett L; Odle B; Cluck D; Freshour J; El-Bazouni H
    Ann Pharmacother; 2016 Apr; 50(4):270-5. PubMed ID: 26783354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
    Sindali K; Rose B; Soueid H; Jeer P; Saran D; Shrivastava R
    Eur J Orthop Surg Traumatol; 2013 May; 23(4):481-6. PubMed ID: 23412293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A RCT study of Rivaroxaban, low-molecular-weight heparin, and sequential medication regimens for the prevention of venous thrombosis after internal fixation of hip fracture.
    Tang Y; Wang K; Shi Z; Yang P; Dang X
    Biomed Pharmacother; 2017 Aug; 92():982-988. PubMed ID: 28605879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group.
    Comp PC; Spiro TE; Friedman RJ; Whitsett TL; Johnson GJ; Gardiner GA; Landon GC; Jové M;
    J Bone Joint Surg Am; 2001 Mar; 83(3):336-45. PubMed ID: 11263636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.
    Turpie AG; Lassen MR; Eriksson BI; Gent M; Berkowitz SD; Misselwitz F; Bandel TJ; Homering M; Westermeier T; Kakkar AK
    Thromb Haemost; 2011 Mar; 105(3):444-53. PubMed ID: 21136019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dabigatran: new drug. Continue to use heparin, a better-known option.
    Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
    Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
    Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apixaban. After hip or knee replacement: LMWH remains the standard treatment.
    Prescrire Int; 2012 Sep; 21(130):201-2, 204. PubMed ID: 23016247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and effectiveness of aspirin and enoxaparin for venous thromboembolism prophylaxis after total hip and knee arthroplasty: a systematic review.
    Nadi S; Vreugdenburg TD; Atukorale Y; Ma N; Maddern G; Rovers M
    ANZ J Surg; 2019 Oct; 89(10):1204-1210. PubMed ID: 30989803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
    Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Hornick P;
    Lancet; 2010 Mar; 375(9717):807-15. PubMed ID: 20206776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
    Samama CM; Laporte S; Rosencher N; Girard P; Llau J; Mouret P; Fisher W; Martínez-Martín J; Duverger D; Deygas B; Presles E; Cucherat M; Mismetti P;
    N Engl J Med; 2020 May; 382(20):1916-1925. PubMed ID: 32223113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: A systematic review and meta-analysis.
    Farey JE; An VVG; Sidhu V; Karunaratne S; Harris IA
    Orthop Traumatol Surg Res; 2021 Feb; 107(1):102606. PubMed ID: 32631716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    Agnelli G; George DJ; Kakkar AK; Fisher W; Lassen MR; Mismetti P; Mouret P; Chaudhari U; Lawson F; Turpie AG;
    N Engl J Med; 2012 Feb; 366(7):601-9. PubMed ID: 22335737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
    Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
    Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.